EP1335707A2 - Novel formulations of carvedilol - Google Patents
Novel formulations of carvedilolInfo
- Publication number
- EP1335707A2 EP1335707A2 EP01273804A EP01273804A EP1335707A2 EP 1335707 A2 EP1335707 A2 EP 1335707A2 EP 01273804 A EP01273804 A EP 01273804A EP 01273804 A EP01273804 A EP 01273804A EP 1335707 A2 EP1335707 A2 EP 1335707A2
- Authority
- EP
- European Patent Office
- Prior art keywords
- carvedilol
- acid
- pharmaceutically acceptable
- organic acid
- formulation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
- A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
Landscapes
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Heart & Thoracic Surgery (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US24291100P | 2000-10-24 | 2000-10-24 | |
US242911P | 2000-10-24 | ||
PCT/US2001/050872 WO2002065834A2 (en) | 2000-10-24 | 2001-10-23 | Novel formulations of carvedilol |
Publications (2)
Publication Number | Publication Date |
---|---|
EP1335707A2 true EP1335707A2 (en) | 2003-08-20 |
EP1335707A4 EP1335707A4 (en) | 2005-07-06 |
Family
ID=22916614
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP01273804A Withdrawn EP1335707A4 (en) | 2000-10-24 | 2001-10-23 | Novel formulations of carvedilol |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP1335707A4 (en) |
JP (1) | JP2004518734A (en) |
AU (1) | AU2001297631A1 (en) |
CA (1) | CA2426811A1 (en) |
WO (1) | WO2002065834A2 (en) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1067910B1 (en) | 1998-04-03 | 2004-05-26 | Egalet A/S | Controlled release composition |
IN191028B (en) * | 2001-05-17 | 2003-09-13 | Sun Pharmaceutical Ind Ltd | |
WO2003024429A1 (en) * | 2001-09-21 | 2003-03-27 | Egalet A/S | Polymer release system |
US20040253310A1 (en) | 2001-09-21 | 2004-12-16 | Gina Fischer | Morphine polymer release system |
US20050019399A1 (en) * | 2001-09-21 | 2005-01-27 | Gina Fischer | Controlled release solid dispersions |
AU2003275953A1 (en) | 2002-11-08 | 2004-06-07 | Egalet A/S | Controlled release carvedilol compositions |
EP1610767B1 (en) | 2003-03-26 | 2011-01-19 | Egalet A/S | Morphine controlled release system |
EP2186510B1 (en) | 2003-03-26 | 2013-07-10 | Egalet Ltd. | Matrix compositions for controlled delivery of drug substances |
ES2662903T3 (en) * | 2003-11-25 | 2018-04-10 | Smithkline Beecham (Cork) Limited | Carvedilol-free base, salts, anhydrous or solvate forms thereof, corresponding pharmaceutical compositions, controlled release formulations, and treatment or administration procedures |
US20050169994A1 (en) * | 2003-11-25 | 2005-08-04 | Burke Matthew D. | Carvedilol free base, salts, anhydrous forms or solvates thereof, corresponding pharmaceutical compositions, controlled release formulations, and treatment or delivery methods |
WO2006091941A2 (en) * | 2005-02-25 | 2006-08-31 | The Regents Of The University Of Michigan | Compositions and methods for treating and preventing cardiomyopathy and heart disease |
HU227490B1 (en) * | 2005-08-26 | 2011-07-28 | Egis Gyogyszergyar Nyilvanosan Muekoedoe Reszvenytarsasag | Sustained release pharmaceutical preparation containing carvedilol |
AU2007281531B2 (en) | 2006-08-01 | 2013-07-04 | Phrixus Pharmaceuticals, Incorporated | Use of poloxamer for the prevention and/or treatment of heart failure |
HU227881B1 (en) * | 2007-02-23 | 2012-05-29 | Egis Gyogyszergyar Nyilvanosan Muekoedoe Reszvenytarsasag | Sustained release pharmaceutical preparation containing carvedilol |
WO2008114276A1 (en) * | 2007-03-16 | 2008-09-25 | Lupin Limited | Novel oral controlled release composition of carvedilol |
EP2150260A2 (en) | 2007-04-05 | 2010-02-10 | Phrixus Pharmaceuticals, Inc. | Compositions and methods for the treatment of heart failure |
AU2008258596B2 (en) | 2007-06-04 | 2013-02-14 | Egalet Ltd | Controlled release pharmaceutical compositions for prolonged effect |
FR2936709B1 (en) * | 2008-10-02 | 2012-05-11 | Ethypharm Sa | ALCOHOL-RESISTANT TABLETS. |
EP2393484A1 (en) | 2009-02-06 | 2011-12-14 | Egalet Ltd. | Immediate release composition resistant to abuse by intake of alcohol |
CA2766179A1 (en) | 2009-06-24 | 2010-12-29 | Egalet Ltd. | Controlled release formulations |
TWI415604B (en) * | 2009-09-29 | 2013-11-21 | Tsh Biopharm Corp Ltd | Controlled release carvediolol formulation |
EP2877161A1 (en) | 2012-07-06 | 2015-06-03 | Egalet Ltd. | Abuse deterrent pharmaceutical compositions for controlled release |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19816036A1 (en) * | 1998-04-09 | 1999-10-14 | Roche Diagnostics Gmbh | Production of pharmaceutical preparations with high disintegration rate containing difficultly soluble active ingredient, e.g. carvedilol |
WO2000000179A1 (en) * | 1998-06-27 | 2000-01-06 | Won Jin Biopharma Co., Ltd. | Solid dispersed preparation of poorly water-soluble drug containing oil, fatty acid or mixtures thereof |
WO2000004902A1 (en) * | 1998-07-23 | 2000-02-03 | Roche Diagnostics Gmbh | Stabilized carvedilol injection solution |
WO2000032174A2 (en) * | 1998-11-27 | 2000-06-08 | F. Hoffmann-La Roche Ag | Pharmaceutical combination preparations of carvedilol and hydrochlorothiazide |
WO2001035958A1 (en) * | 1999-11-15 | 2001-05-25 | Smithkline Beecham Corporation | Carvedilol methanesulfonate |
WO2001074356A1 (en) * | 2000-04-03 | 2001-10-11 | F. Hoffmann-La Roche Ag | Concentrated solutions of carvedilol |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19637082A1 (en) * | 1996-09-12 | 1998-03-19 | Boehringer Mannheim Gmbh | Rapidly disintegrating pellets |
US6056968A (en) * | 1997-03-11 | 2000-05-02 | Darwin Discovery Limited | Pharmaceutical drug dosage forms providing different release rates |
-
2001
- 2001-10-23 WO PCT/US2001/050872 patent/WO2002065834A2/en not_active Application Discontinuation
- 2001-10-23 EP EP01273804A patent/EP1335707A4/en not_active Withdrawn
- 2001-10-23 AU AU2001297631A patent/AU2001297631A1/en not_active Abandoned
- 2001-10-23 CA CA002426811A patent/CA2426811A1/en not_active Abandoned
- 2001-10-23 JP JP2002565411A patent/JP2004518734A/en active Pending
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19816036A1 (en) * | 1998-04-09 | 1999-10-14 | Roche Diagnostics Gmbh | Production of pharmaceutical preparations with high disintegration rate containing difficultly soluble active ingredient, e.g. carvedilol |
WO2000000179A1 (en) * | 1998-06-27 | 2000-01-06 | Won Jin Biopharma Co., Ltd. | Solid dispersed preparation of poorly water-soluble drug containing oil, fatty acid or mixtures thereof |
WO2000004902A1 (en) * | 1998-07-23 | 2000-02-03 | Roche Diagnostics Gmbh | Stabilized carvedilol injection solution |
WO2000032174A2 (en) * | 1998-11-27 | 2000-06-08 | F. Hoffmann-La Roche Ag | Pharmaceutical combination preparations of carvedilol and hydrochlorothiazide |
WO2001035958A1 (en) * | 1999-11-15 | 2001-05-25 | Smithkline Beecham Corporation | Carvedilol methanesulfonate |
WO2001074356A1 (en) * | 2000-04-03 | 2001-10-11 | F. Hoffmann-La Roche Ag | Concentrated solutions of carvedilol |
Non-Patent Citations (1)
Title |
---|
See also references of WO02065834A2 * |
Also Published As
Publication number | Publication date |
---|---|
EP1335707A4 (en) | 2005-07-06 |
AU2001297631A1 (en) | 2002-09-04 |
WO2002065834A8 (en) | 2003-06-26 |
AU2001297631A8 (en) | 2005-09-15 |
CA2426811A1 (en) | 2002-08-29 |
WO2002065834A3 (en) | 2002-10-03 |
WO2002065834A2 (en) | 2002-08-29 |
JP2004518734A (en) | 2004-06-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2002065834A2 (en) | Novel formulations of carvedilol | |
US7674479B2 (en) | Sustained-release bupropion and bupropion/mecamylamine tablets | |
US8747898B2 (en) | Controlled release oral dosage form | |
JP3806740B2 (en) | Drug delivery composition | |
JP5739080B2 (en) | Sustained release formulation of levetiracetam | |
US20120301541A1 (en) | Compressed core for pharmaceutical composition | |
US20020064555A1 (en) | Proton pump inhibitor formulation | |
EP1233768A1 (en) | Carvedilol methanesulfonate | |
GB2128088A (en) | Oral mopidamol preparations | |
EP1820506B1 (en) | Dipyridamole extended-release formulations and process for preparing same | |
US20040019096A1 (en) | Novel formulations of carvedilol | |
EP2468361B1 (en) | Vildagliptin Formulations | |
EP0951278A2 (en) | Sustained release cisapride mini-tablet formulation | |
JP6148252B2 (en) | New formulation | |
TW201206501A (en) | Pharmaceutical compositions comprising hydromorphone and naloxone | |
JP2023513249A (en) | Omecamtib mecarbyl formulation | |
JP2015500853A (en) | Immediate release multi-unit pellet system | |
US8703191B2 (en) | Controlled-release pharmaceutical tablets | |
AU2007263261B2 (en) | Galenical formulations of aliskiren and hydrochlorothiazide | |
EP1178780B1 (en) | Multiparticulate controlled release selective serotonin reuptake inhibitor formulations | |
WO2009027786A2 (en) | Matrix dosage forms of varenicline | |
CZ287149B6 (en) | Pharmaceutical preparation containing gemfibrozil | |
WO2007129329A2 (en) | Extended release pharmaceutical formulation comprising venlafaxine hydrochloride | |
JP2002518330A (en) | Treatment method | |
JP2009525953A (en) | Sustained release formulation of divalproic acid and its derivatives |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20030519 |
|
AK | Designated contracting states |
Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR |
|
AX | Request for extension of the european patent |
Extension state: AL LT LV MK RO SI |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20050523 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: 7A 61K 31/403 B Ipc: 7A 61K 9/62 B Ipc: 7A 61K 9/58 B Ipc: 7A 61K 9/52 B Ipc: 7A 61K 9/30 B Ipc: 7A 61K 9/26 B Ipc: 7A 61K 9/22 A |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20070430 |